Eli Lilly Enters $1.9 Billion Gene-Editing Partnership with Ascidian Therapeutics

Eli Lilly has entered a collaboration and licensing agreement with Boston-based Ascidian Therapeutics to develop gene-editing treatments for inherited kidney diseases, potentially worth up to $1.9 billion. The partnership combines Ascidian's RNA exon-editing platform with Lilly’s capabilities in clinical development and commercialization.

By Cris Tolomia Wed, June 3, 2026 at 5:02 PM GMT+3 2 min read · Yahoo Finance · June 3, 2026, 14:02 UTC

Tickers: $LLY

Topics: gene-editing kidney disease pharmaceuticals RNA exon editing

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC
CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans Motley Fool · November 12, 2026, 17:40 UTC
NUGL Reports Third Quarter Net Income of $0.19 Million and Revenue of $1.04 Million Seeking Alpha · November 12, 2026, 17:38 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC